https://vogenx.com/vogenx-inc-announces-initiation-of-phase-2-clinical-study-of-mizagliflozin-for-post-bariatric-hypoglycemia-copy/2025-01-22T20:49:29+00:00https://vogenx.com/vogenx-inc-to-present-new-phase-2-clinical-data-on-mizagliflozin-at-the-endocrine-society-endo-2023-annual-conference/2023-12-13T18:13:56+00:00https://vogenx.com/vogenx-inc-announces-initiation-of-phase-2-clinical-study-of-mizagliflozin-for-post-bariatric-hypoglycemia/2023-12-13T18:16:51+00:00https://vogenx.com/vogenx-inc-announces-completion-of-phase-2-clinical-study-of-mizagliflozin-for-post-bariatric-hypoglycemia/2023-12-13T18:15:31+00:00https://vogenx.com/vogenx-announces-positive-results-in-phase-2-study-of-mizagliflozin-in-post-bariatric-hypoglycemia-2/2023-12-13T18:13:07+00:00https://vogenx.com/vogenx-announces-initiation-of-phase-2-clinical-study-of-mizagliflozin-for-post-bariatric-hypoglycemia/2023-12-13T18:10:49+00:00https://vogenx.com/vogenx-completes-enrollment-of-phase-2-trial-of-mizagliflozin-for-post-bariatric-hypoglycemia/2024-02-14T23:10:34+00:00https://vogenx.com/vogenx-completes-dosing-of-last-patient-in-phase-2-clinical-study-of-mizagliflozin-for-the-treatment-of-post-bariatric-hypoglycemia/2024-04-02T13:15:57+00:00https://vogenx.com/vogenx-announces-positive-results-in-second-phase-2-study-of-mizagliflozin-in-post-bariatric-hypoglycemia/2024-06-26T17:47:29+00:00https://vogenx.com/vogenx-inc-to-present-phase-2-clinical-data-on-mizagliflozin-at-the-endocrine-society-endo-2025-annual-conference/2025-04-17T18:07:38+00:00